NCT01203345View on ClinicalTrials.gov

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

2,416

Participants

Timeline

Start Date

January 31, 1988

Primary Completion Date

March 31, 1991

Study Completion Date

March 31, 1991

Conditions
Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational AgeInfant, PrematureSepsis
Interventions
DRUG

IVIG

The infants received their first dose of study drug within 24 hours of randomization.

DRUG

Placebo

An equal volume of 5 percent albumin solution

Trial Locations (8)

20052

George Washington University, Washington D.C.

33136

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

38163

University of Tennessee, Memphis

44106

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland

48201

Wayne State University, Detroit

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

05405

University of Vermont, Burlington

All Listed Sponsors
lead

NICHD Neonatal Research Network

NETWORK

NCT01203345 - Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection | Biotech Hunter | Biotech Hunter